# Sekisui Diagnostics invests £14.4M in cGMP biopharma CDMO capacity expansion

Sekisui Diagnostics announced a £14.4 million investment to expand cGMP microbial fermentation and purification capacity at its Maidstone, Kent site, to be completed by the second half of 2022.

- Type: Expansion
- Announced: 2020-07-29
- Where: Maidstone, Kent, United Kingdom
- Value: $18.5M (14.4M GBP)
- Starts operating: Q3 2022
- Status: announced
- Capacity: up to 1,000L fermentation scale
- Products: cGMP microbial fermentation and purification suites for biopharma CDMO
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Sekisui Diagnostics](https://endata.com/companies/25526.md)

## Sources

- [newswire.ca](https://www.newswire.ca/fr/news-releases/sekisui-diagnostics-invests-ps14-4-million-in-cgmp-biopharma-cdmo-capacity-895795107.html), 2020-07-29: "This investment represents our commitment to serve our Biopharma customers with much needed cGMP microbial CDMO production capacity."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.